CRS and ICANS Treatment
A Phase II Pilot Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to Chimeric Antigen Receptor T-Cell Therapy (CAR-T) in Hematological Malignancies
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 30 patients (estimated)
- Sponsors
- University of Alabama at Birmingham
- Tags
- Monoclonal Antibody, Interleukin 6 (IL-6)
- Trial Type
- Supportive
- Last Update
- 2 weeks ago
- SparkCures ID
- 1897
- NCT Identifier
- NCT04975555
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.